Who founded Havah Therapeutics?

Havah Therapeutics was founded by Stephen N Birrell in 2023.

How much funding has Havah Therapeutics raised?

Havah Therapeutics has disclosed $507.4K raised across 1 round.

Where is Havah Therapeutics headquartered?

Havah Therapeutics is headquartered in Longmont, US.

Havah Therapeutics

Longmont, US · Founded 2023 · Delaware corporation

Find your way into Havah Therapeutics

165 people in our graph share verified history with the Havah Therapeutics team — schools, employers, funds. One of them is your warm intro.

Alex Cheeunlockedknows Matt Brewer · together at Ashvattha Therapeutics, Inc. (overlapped)

×11knows the team · via Intrexon Corporation

HavaH Therapeutics develops T+Ai, a subcutaneous extended-release pellet combining testosterone and anastrozole, aimed at preventing and treating hormone receptor positive breast cancer, including ductal carcinoma in situ (DCIS) and ER+ disease. The clinical-stage company targets the intra-mammary hormonal balance to slow tumor growth and reduce the need for surgery.

Biotech Deep Tech Healthtech

Founders & leadership

Havah Therapeutics was founded in 2023 by Stephen N Birrell.

Stephen N Birrell Founder & AdvisorDr. Stephen Birrell is a Fellow of the Royal Australasian College of Surgeons with over 30 years of experience in breast oncology and medical research. He founded Havah Therapeutics and Wellend Health, an Australian breast health clinic, and holds patents related to breast cancer risk reduction and aromatase inhibitor therapies.

Matt Brewer CEO & PresidentMatt Brewer is CEO and President of Havah Therapeutics, a clinical-stage company developing T+Ai, a subcutaneous extended-release pellet combining testosterone and anastrozole for hormone receptor positive breast cancer treatment and prevention.

John AdairCFO

Ronald MartellNamed on SEC filing

Jim WeissBoard Member and Investor

Reported raises · per SEC filings

Form D private placements

$507.4K disclosed across 1 round · 2024

▶$507.4KraisedMay 2024 · 14 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Ronald MartellDirector
Matthew BrewerExecutive Officer, Director
Jim WeissDirector

Offering amount: $507.4K
Amount sold: $507.4K
First sale: May 2024
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Havah Therapeutics do?: HavaH Therapeutics develops T+Ai, a subcutaneous extended-release pellet combining testosterone and anastrozole, aimed at preventing and treating hormone receptor positive breast cancer, including ductal carcinoma in situ (DCIS) and ER+ disease. The clinical-stage company targets the intra-mammary hormonal balance to slow tumor growth and reduce the need for surgery.
Who founded Havah Therapeutics?: Havah Therapeutics was founded by Stephen N Birrell in 2023.
How much funding has Havah Therapeutics raised?: Havah Therapeutics has disclosed $507.4K raised across 1 round.
Where is Havah Therapeutics headquartered?: Havah Therapeutics is headquartered in Longmont, US.